NCT06014424 is a Phase 2 clinical trial investigating the efficacy of cannabidiol (CBD) for managing agitation in Alzheimer's disease patients. The study is conducted at Sunnybrook Health Sciences Centre in Toronto, Canada.
| Attribute | Value |
|---|---|
| NCT ID | NCT06014424 |
| Phase | Phase 2 |
| Status | Recruiting |
| Study Type | Interventional |
| Design | Cross-over trial |
| Intervention | CBD capsules |
| Indication | Agitation in Alzheimer's Disease |
| Sponsor | Sunnybrook Health Sciences Centre |
| Location | Toronto, Ontario, Canada |
This cross-over trial evaluates CBD as a pharmacological intervention for behavioral and psychological symptoms of dementia (BPSD), specifically agitation in AD patients. Agitation is one of the most challenging symptoms of Alzheimer's disease, affecting patient quality of life and caregiver burden.
Cannabidiol (CBD) has shown potential in preclinical models for:
Reduction in agitation scores (likely using standardized scales such as Cohen-Mansfield Agitation Inventory or Neuropsychiatric Inventory)
CBD interacts with the endocannabinoid system through: